Publications by authors named "Ludwig Kappos"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

92,477

Total Likes

8,515

Extended Reach

180,955

Social Features

20
P
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
Ralf Gold, Ludwig Kappos, Douglas L Arnold, Amit Bar-Or, Gavin Giovannoni, Krzysztof Selmaj, Carlo Tornatore, Marianne T Sweetser, Minhua Yang, Sarah I Sheikh

N Engl J Med· September 2012

Videos about Article: user user

2 9 15 6 11

View All Article and Social Media Activity
D
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".
Chris H Polman, Stephen C Reingold, Gilles Edan, Massimo Filippi, Hans-Peter Hartung, Ludwig Kappos, Fred D Lublin, Luanne M Metz, Henry F McFarland, Paul W O'Connor

Ann Neurol· December 2005

Videos about Article: user user

2 1 3 2 3

View All Article and Social Media Activity
T
TIME: Tractography-Informed myelin estimation.
Sara Bosticardo, Matteo Battocchio, Mario Ocampo-Pineda, Alessandro Cagol, Po-Jui Lu, Ludwig Kappos

Neuroimage Clin· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of disease-modifying therapies on brain volume loss and disability accumulation in multiple sclerosis: a systematic review and network meta-analysis.
Alessandro Cagol, Sabine Schaedelin, Roxanne Pretzsch, Ludwig Kappos, Maria Pia Sormani

Lancet Reg Health Eur· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age- and BMI-Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment Response.
Maximilian Einsiedler, Aleksandra Maleska Maceski, Sofia Sandgren, Johanna Oechtering, Sabine Schaedelin, Ludwig Kappos

Ann Clin Transl Neurol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker discovery using NUcleic Acid-Linked Immuno-Sandwich Assay in multiple sclerosis patients experiencing progression independent of relapse activity.
Sofia Sandgren, Aleksandra Maleska Maceski, Pascal Benkert, Maximilian Einsiedler, Sabine Schaedelin, Ludwig Kappos

Mult Scler· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial.
Krzysztof W Selmaj, Lawrence Steinman, Giancarlo Comi, Amit Bar-Or, Douglas L Arnold, Ludwig Kappos

Mult Scler· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis.
Aleksandra Maleska Maceski, Pascal Benkert, Maximilian Einsiedler, Sabine Schaedelin, Johanna Oechtering, Ludwig Kappos

Brain· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-Year Safety and Efficacy Outcomes with Ofatumumab in Patients with Relapsing Multiple Sclerosis.
Stephen L Hauser, Jeffrey A Cohen, Jérôme de Sèze, Sven G Meuth, Paul S Giacomini, Ludwig Kappos

Neurol Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Ponesimod as add-on treatment in patients with active relapsing multiple sclerosis under dimethyl fumarate (POINT): A phase 3, randomized, placebo-controlled clinical trial.
Ludwig Kappos, Michel Burcklen, Daniele D'Ambrosio, Robert J Fox, Mark S Freedman

Mult Scler Relat Disord· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AI-driven reclassification of multiple sclerosis progression.
Habib Ganjgahi, Dieter A Häring, Piet Aarden, Gordon Graham, Yang Sun, Ludwig Kappos

Nat Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria.
Xavier Montalban, Christine Lebrun-Frénay, Jiwon Oh, Georgina Arrambide, Marcello Moccia, Ludwig Kappos

Lancet Neurol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2024 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI for the diagnosis of multiple sclerosis.
Frederik Barkhof, Daniel S Reich, Jiwon Oh, Maria A Rocca, David K B Li, Ludwig Kappos

Lancet Neurol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Performance of Composite Endpoints Defining Progression Independent of Relapse Activity in Multiple Sclerosis.
Ludwig Kappos, Sean Yiu, Jason Reucassel, Jiwon Oh, Cristina Granziera

Ann Clin Transl Neurol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brain atrophy and associations with long-term disability and cognitive function in participants with relapsing multiple sclerosis treated with ozanimod: Results from phase 3 and open-label extension trials.
Jeffrey A Cohen, Douglas L Arnold, John DeLuca, Hans-Peter Hartung, Ludwig Kappos

Mult Scler· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Somatosensory Profile of Central Post Stroke Pain of Thalamic Origin: Findings of a Quantitative Sensory Testing Study.
Kristel Berati, Lukas Enz, Priska Zuber, Katarina Alexandra Ebner, Shaumiya Sellathurai, Ludwig Kappos

Eur J Pain· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unraveling Microstructural and Macrostructural Brain Age Dynamics in Multiple Sclerosis.
Xinjie Chen, Po-Jui Lu, Mario Ocampo-Pineda, Alessandro Cagol, Sabine Anna Schaedelin, Ludwig Kappos

Neurol Neuroimmunol Neuroinflamm· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Strategies and Disease Activity During Pregnancy and Postpartum: Real-World Data From the Swiss Multiple Sclerosis Cohort.
Maximilian Einsiedler, Chiara Zecca, Lisa Hofer, Pascal Benkert, Cathrine Axfors, Ludwig Kappos

Neurol Clin Pract· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression.
Marianna Cortese, Xiaojing Peng, Gilles Edan, Mark S Freedman, Hans-Peter Hartung, Ludwig Kappos

Neurology· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi Study.
Özgür Yaldizli, Pascal Benkert, Lutz Achtnichts, Amit Bar-Or, Viviane Bohner-Lang, Ludwig Kappos

Mult Scler· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intrathecal Inflammatory Profile and Gray Matter Damage Predict Progression Independent of Relapse Activity in Early Multiple Sclerosis.
Damiano Marastoni, Elisa Colato, Matteo Foschi, Agnese Tamanti, Stefano Ziccardi, Ludwig Kappos

Neurol Neuroimmunol Neuroinflamm· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Uncovering a bias in estimated treatment effects on PIRA in multiple sclerosis clinical trials.
Noemi Montobbio, Francesca Bovis, Alessio Signori, Luca Carmisciano, Irene Schiavetti, Ludwig Kappos

EBioMedicine· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis Cohort.
Alessandro Cagol, Sabine Schaedelin, Mario Ocampo-Pineda, Pascal Benkert, Lester Melie-Garcia, Ludwig Kappos

J Neurol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Music therapy with a monochord in multiple sclerosis ("MUTIMS"): .
Jenni Kuhlmann, Katarina Ebner, Andrea Zimmer, Nikki Rommers, Nuria Cerdá-Fuertes, Ludwig Kappos

Mult Scler J Exp Transl Clin· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glial Fibrillary Acidic Protein as a Marker of Disease in Relapsing Multiple Sclerosis: Post Hoc Analysis of Phase 3 Ozanimod Trials.
Sarah Harris, Giancarlo Comi, Bruce A C Cree, Douglas L Arnold, Lawrence Steinman, Ludwig Kappos

Eur J Neurol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retinal neuronal loss and progression independent of relapse activity in multiple sclerosis.
Federico Burguet Villena, Nuria Cerdá-Fuertes, Lisa Hofer, Sabine Schädelin, Shaumiya Sellathurai, Ludwig Kappos

J Neurol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personalized Treatment Response in Progressive MS: Can the Patient's Profile Influence the Outcome?
Francesca Bovis, Ludwig Kappos, Sophie Arnould, Goeril Karlsson, Maria Pia Sormani

Brain Behav· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis